PIK3CA and cancer: Although improvements in patient stratification strategies and the development of rational drug combinations are rapidly extending the clinical utility of PI3K inhibitors in the treatment of cancer patients, managing adverse effects, such as infections and inflammation, as well as drug resistance, remains a challenge [76,86].